U.S. Markets open in 1 hr 16 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
87.85+0.10 (+0.11%)
As of 1:58PM CEST. Market open.
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
Previous Close87.75
Open87.31
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range87.29 - 88.35
52 Week Range62.50 - 92.97
Volume676,491
Avg. Volume2,327,189
Market Cap110.58B
BetaN/A
PE Ratio (TTM)24.19
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals2 hours ago

    ​Sanofi Genzyme takes on world’s top-selling drugs with new approval

    With Monday’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for that same disease: give it a lower price. Cambridge-based Sanofi Genzyme (SNY) and Tarrytown, N.Y.-based Regeneron (REGN) will market their new drug, which has the generic name of sarilumab, under the name of Kevzara. Rheumatoid arthritis affects about 1.3 million Americans, mostly women, and Kevzara is approved for those with moderate to severe forms of the disease that aren’t well treated by other drugs.

  • Reuters14 hours ago

    Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

    The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. The drug, sarilumab, which will be sold under the brand name Kevzara, will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses, which the companies said was about 30 percent lower than the list price for the two most widely used rival medicines in the highly competitive space. The approval marks a second major regulatory victory for the two companies in recent weeks after their potential blockbuster treatment for severe atopic dermatitis, Dupixent, won U.S. approval in late March.

  • Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
    Zacks16 hours ago

    Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

    Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).